Oragenics Files S-1/A Amendment
Ticker: OGEN · Form: S-1/A · Filed: Dec 31, 2024 · CIK: 1174940
Sentiment: neutral
Topics: sec-filing, s-1/a, registration
TL;DR
Oragenics filed an S-1/A amendment, likely for a stock offering. Keep an eye on share dilution.
AI Summary
Oragenics, Inc. filed a Pre-Effective Amendment No. 1 to its Form S-1 Registration Statement on December 31, 2024. This filing relates to the registration of securities under the Securities Act of 1933. The company, incorporated in Florida with IRS number 59-3410522, has its principal executive offices at 1990 Main Street, Suite 750, Sarasota, Florida 34236.
Why It Matters
This amendment to the S-1 registration statement indicates Oragenics is moving forward with a securities offering, which could impact its capital structure and future operations.
Risk Assessment
Risk Level: medium — S-1 filings often precede stock offerings, which can lead to dilution and price volatility for existing shareholders.
Key Numbers
- 333-283927 — SEC File Number (Identifies this specific registration)
- 59-3410522 — IRS Number (Company's tax identification number)
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- December 31, 2024 (date) — Filing Date
- Florida (location) — State of Incorporation
- 1990 Main Street, Suite 750, Sarasota, Florida 34236 (address) — Principal Executive Offices
- Janet Huffman (person) — Chief Financial Officer
- Mark A. Catchur, Esq. (person) — Legal Counsel
- Shumaker, Loop & Kendrick, LLP (company) — Legal Counsel
FAQ
What is the purpose of this S-1/A filing?
This is a Pre-Effective Amendment No. 1 to a Form S-1 Registration Statement, indicating Oragenics is updating its registration for securities.
When was this amendment filed?
The amendment was filed with the SEC on December 31, 2024.
Where is Oragenics, Inc. headquartered?
Oragenics, Inc.'s principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, Florida 34236.
Who is listed as an officer of Oragenics in this filing?
Janet Huffman is listed as the Chief Financial Officer.
What is the SEC file number for this registration?
The SEC file number for this registration is 333-283927.
Filing Stats: 4,467 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-12-31 11:47:28
Key Financial Figures
- $0.001 — of one share of common stock, par value $0.001 per share (“Common Stock”)
- $0.33 — at an assumed public offering price of $0.33 per Unit, the last reported sale price
- $0 — d to the public in this offering, minus $0.001, and the exercise price of each Pre
- $0.339 — ncluding one Pre-Funded Warrant will be $0.339. (2) We will pay the Placement Agent
- $350,000 — cement agent fee, will be approximately $350,000. The delivery of the shares of Common
- $1,000,000 — acquisition, we paid Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in
- $500,000 — Odyssey a total of $1,000,000 in cash, $500,000 of which was paid in October, 2023 and
- $6.9 billion — for concussion treatment was valued at $6.9 billion in 2020 and is forecast to reach $8.9 b
- $8.9 billion — illion in 2020 and is forecast to reach $8.9 billion by 2027, according to Grandview Researc
Filing Documents
- forms-1a.htm (S-1/A) — 758KB
- ex5-1.htm (EX-5.1) — 22KB
- ex23-1.htm (EX-23.1) — 5KB
- ex23-2.htm (EX-23.2) — 5KB
- ex5-1_001.jpg (GRAPHIC) — 21KB
- forms-1_001.jpg (GRAPHIC) — 4KB
- forms-1_002.jpg (GRAPHIC) — 12KB
- 0001493152-24-052623.txt ( ) — 843KB
USE OF PROCEEDS
USE OF PROCEEDS 19 DIVIDEND POLICY 19 CAPITALIZATION 20
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 22
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 25 PLAN OF DISTRIBUTION 29 EXPERTS 32 LEGAL MATTERS 32 INCORPORATION BY REFERENCE 32 WHERE YOU CAN FIND MORE INFORMATION 34 ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “Incorporation of Certain Information by Reference,” before deciding to invest in our securities. You should rely only on the information contained in this prospectus. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you, and we take no responsibility for any other information others may give you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our o